Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

NCT03076203 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Prostate Carcinoma Metastatic to the Bone
Stage IV Prostate Adenocarcinoma
Hormone-refractory Prostate Cancer

Interventions

DRUG: Niraparib
RADIATION: Radium Ra 223 Dichloride

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Collaborators

[object Object]
[object Object]
[object Object]